Detalhe da pesquisa
1.
Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.
Diabetes Obes Metab
; 26(2): 473-481, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37853960
2.
Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes.
Diabetes Obes Metab
; 26(6): 2446-2455, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38528819
3.
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Lancet
; 398(10300): 583-598, 2021 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34370970
4.
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
JAMA
; 327(6): 534-545, 2022 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35133415
5.
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
Diabetes Obes Metab
; 22(6): 938-946, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31984598
6.
Why are not There More Bayesian Clinical Trials? Perceived Barriers and Educational Preferences Among Medical Researchers Involved in Drug Development.
Ther Innov Regul Sci
; 57(3): 417-425, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34978048
7.
Why are There not More Bayesian Clinical Trials? Ability to Interpret Bayesian and Conventional Statistics Among Medical Researchers.
Ther Innov Regul Sci
; 57(3): 426-435, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36496452
8.
Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.
Diabetes Ther
; 14(11): 1833-1852, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37526908
9.
Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
Lancet Diabetes Endocrinol
; 10(6): 407-417, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35468321
10.
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
Lancet Diabetes Endocrinol
; 10(6): 393-406, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35468325
11.
Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
J Clin Endocrinol Metab
; 106(2): 388-396, 2021 01 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-33236115
12.
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.
Diabetes Care
; 43(6): 1352-1355, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32291277